Drugs / Bambuterol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01796730 | Feb 2013 → Oct 2014 | chronic obstructive pulmonary disease | The First Affiliated Hospital of Guangzhou Medical University | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01566565 Comparator | Mar → May 2012 | pulmonary hypertension | Norwegian Armed Forces Medical Service | Completed | No outcome recorded |
| Phase 4 | NCT02002754 Comparator | Jun 2012 → Mar 2014 | chronic bronchitis, cough variant asthma | The First Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| — | NCT02790047 Background | Oct 2016 → Jan 2018 | chronic obstructive pulmonary disease | Khon Kaen University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bambuterol | “Bambuterol (oral)” NCT02790047 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL521589 ↗ |
| Modality | Small molecule | — CHEMBL521589 ↗ |
| Route | Oral | “Periods I and II consist of the oral administration of either a single dose of theophylline or bambuterol alone” NCT01566565 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL521589 ↗ |